Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative outcomes and characteristics of biliary, alcoholic and drug-induced pancreatitis based on the National Inpatient Sample (2016-2021).

Annals of gastroenterology·2026
Same author

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same author

SNAP Participation and Cancer Screening for Adults With Food Insecurity.

JAMA network open·2026
Same author

A novel bimanual endoluminal robotic platform compatible with standard gastroscopes for endoscopic submucosal dissection: preclinical feasibility and ergonomic evaluation.

Surgical endoscopy·2026
Same author

Housing and utility hardship among adults with gastrointestinal cancer: differences by housing tenure and employment status.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026
Same author

Gastrointestinal Endoscopic Interventions During Antithrombotic Therapy: A Comprehensive Review of Bleeding Risk and Periprocedural Management.

Cardiology in review·2026

Related Experiment Video

Updated: Jun 4, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

DOAC Pharmacokinetics in Malabsorptive States.

Muhammad Qasim Chaudhry1, Helly Patel2, Jaishkar Ramesh3

  • 1From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.

Cardiology in Review
|June 3, 2026
PubMed
Summary

Direct oral anticoagulants (DOACs) may be less effective in patients with malabsorption. Warfarin is recommended for severe malabsorption, while DOACs like rivaroxaban and apixaban show promise in stable post-bariatric surgery patients.

Keywords:
direct oral anticoagulantsmalabsorptionwarfarin

More Related Videos

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
08:42

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport

Published on: November 27, 2016

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Internal Medicine

Background:

  • Direct oral anticoagulants (DOACs) are increasingly used for stroke prevention and venous thromboembolism treatment.
  • Their efficacy depends on adequate gastrointestinal absorption, which can be compromised in malabsorptive conditions.

Purpose of the Study:

  • To review the effectiveness of DOACs in patients with gastrointestinal malabsorption.
  • To provide guidance on anticoagulant selection in specific malabsorptive scenarios.

Main Methods:

  • Literature review of studies investigating DOAC pharmacokinetics and efficacy in malabsorptive states.
  • Analysis of current guidelines regarding anticoagulant use post-bariatric surgery and in short bowel syndrome.

Main Results:

  • Rivaroxaban and apixaban are effective in stable patients post-bariatric surgery (e.g., sleeve gastrectomy, Roux-en-Y gastric bypass).
  • Dabigatran is less effective due to its reliance on gastric acidity for absorption.
  • Warfarin is the recommended anticoagulant for severe malabsorption, such as very short bowel syndrome, due to its monitorable effect.
  • DOACs are generally not recommended during the acute postoperative period (0-4 weeks).

Conclusions:

  • Anticoagulant choice in malabsorptive conditions requires careful consideration of the specific drug and patient status.
  • Drug-specific assays (anti-Xa, dilute thrombin time) are crucial for monitoring DOAC absorption when used.
  • Individualized treatment strategies are necessary to ensure effective anticoagulation in patients with compromised GI absorption.